RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 201 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2023. The put-call ratio across all filers is 0.72 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $255,473 | +77.0% | 34,063 | +135.3% | 0.00% | +33.3% |
Q1 2024 | $144,346 | +7.6% | 14,478 | +6.4% | 0.00% | +50.0% |
Q4 2023 | $134,136 | +111.5% | 13,604 | +64.1% | 0.00% | 0.0% |
Q3 2023 | $63,419 | -54.2% | 8,290 | -55.2% | 0.00% | -60.0% |
Q2 2023 | $138,330 | +138230.0% | 18,518 | +23.9% | 0.01% | +66.7% |
Q1 2023 | $100 | +455.6% | 14,944 | +550.0% | 0.00% | +200.0% |
Q4 2022 | $18 | -100.0% | 2,299 | -85.1% | 0.00% | -66.7% |
Q3 2022 | $164,000 | +320.5% | 15,411 | +223.6% | 0.00% | +200.0% |
Q2 2022 | $39,000 | +85.7% | 4,762 | +62.1% | 0.00% | – |
Q1 2022 | $21,000 | -70.0% | 2,938 | -28.5% | 0.00% | -100.0% |
Q4 2021 | $70,000 | +400.0% | 4,109 | +607.2% | 0.00% | – |
Q3 2021 | $14,000 | -84.6% | 581 | -76.9% | 0.00% | -100.0% |
Q2 2021 | $91,000 | – | 2,512 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
Artal Group S.A. | 960,204 | $7,403 | 0.41% |